Castro HHG, et al. – This research was designed to assess multimorbidity profile, focusing on the Charlson Comorbidity Index (CCI) validated by Goldstein for ischaemic stroke (IS) patients, a score that measures a burden of comorbidities and its related mortality in the long–term survival of the EMMA Study (Study of Stroke Mortality and Morbidity). In the EMMA study, a high burden of comorbidities described an independent predictor of poor prognosis increasing the risk of dying by 2 to 3 times among IS up to 9 years. The inclusion of other cerebrovascular risk factors (CVRF) like atrial fibrillation (AF) and stroke recurrence slightly modified all–cause mortality risk.